natgillin/translations-raw huggingface dataset:
In patients receiving tenofovir disoproxil fumarate, rare events of renal impairment, renal failure and proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have been reported.
Pri bolnikih, ki so prejemali dizoproksiltenofovirijev fumarat, so poročali o redkih dogodkih ledvične okvare, ledvične odpovedi in proksimalne ledvične tubulopatije (vključno s Fanconijevim sindromom), ki včasih vodijo k anomalijam na kosteh (redko prispevajo k zlomom).
In patients receiving warfarin, INR is increased by administration of bivalirudin.
Pri bolnikih, ki prejemajo varfarin, se z uporabo bivalirudina INR poveča.
In patients receiving ZALTRAP, the adverse reactions in patients with mild renal impairment at baseline in three Phase III placebo-controlled clinical studies (N=352) were comparable with those of patients without renal impairment (N=642).
V treh s placebom kontroliranih kliničnih študijah III. faze so bili neželeni učinki med bolniki, ki so prejemali zdravilo ZALTRAP in so izhodiščno imeli blago okvaro ledvic (n = 352), primerljivi kot med bolniki brez okvare ledvic (n = 642).
In patients refractory to, or relapsing within 3 months after cisplatin therapy (n = 186), the response rate was 10 %.
Pri bolnicah, ki se jim je bolezen kljub zdravljenju s cisplatinom ponovila v roku 3 mesecev, ali ki se niso odzvale na zdravilo (n = 186), pa je bila odzivnost 10 %.
In patients refractory to, or relapsing within 3 months after cisplatin therapy (n = 186), the response rate was 10%.
Pri bolnicah, ki se jim je bolezen kljub zdravljenju s cisplatinom ponovila v roku 3 mesecev, ali ki se niso odzvale na zdravilo (n = 186), pa je bila odzivnost 10 %.
In patients scheduled for major elective orthopaedic surgery the cause of anaemia should be established and treated, if possible, before the start of Retacrit treatment.
Pri bolnikih, pri katerih je predviden večji elektivni ortopedski kirurški poseg, je treba ugotoviti vzrok za anemijo in jo zdraviti pred začetkom zdravljenja z zdravilom Retacrit, če je to mogoče.
In patients scheduled for major elective orthopaedic surgery with a pre-treatment haemoglobin of > 10 to ≤ 13 g/dl, epoetin alfa has been shown to decrease the risk of receiving allogeneic transfusions and hasten erythroid recovery (increased haemoglobin levels, haematocrit levels, and reticulocyte counts).
Pokazalo se je, da epoetin alfa pri bolnikih, naročenih na večji elektivni ortopedski kirurški poseg s hemoglobinom pred zdravljenjem > 10 do ≤ 13 g/dl, zmanjšuje tveganje za prejem alogenske transfuzije in pospeši eritroidno okrevanje (povečane ravni hemoglobina, ravni hematokrita in števila retikulocitov).
In patients scheduled for major elective orthopaedic surgery with a pretreatment haemoglobin of > 10 to ≤ 13 g/dl, epoetin alfa has been shown to decrease the risk of receiving allogeneic transfusions and hasten erythroid recovery (increased haemoglobin levels, haematocrit levels, and reticulocyte counts).
Pokazalo se je, da epoetin alfa pri bolnikih, naročenih na večji elektivni ortopedski kirurški poseg s hemoglobinom pred zdravljenjem > 10 do ≤ 13 g/dl, zmanjšuje tveganje za prejem alogenske transfuzije in pospeši eritroidno okrevanje (povečane ravni hemoglobina, ravni hematokrita in števila retikulocitov).
In patients started on the lower strength inhaler the higher strength inhaler may be used if the asthma is not adequately controlled.
Pri bolnikih, ki so začeli z uporabo inhalatorja nižje jakosti, se lahko v primeru neustrezno obvladane astme uporabi inhalator višje jakosti.
In patients starting or stopping
odmerek lamotrigina in so začeli
In patients suffering from acute coronary syndrome:
Bolniki z akutnim koronarnim sindromom
In patients suffering from epilepsy or brain lesions the likelihood of convulsions during the examination may be increased.
Pri bolnikih z epilepsijo ali lezijami v možganih se lahko verjetnost konvulzij med preiskavo poveča.
In patients taking amlodipine alone the following additional side effects have been reported:
Pri bolnikih, ki so jemali samo amlodipin, so poročali še o naslednjih neželenih učinkih:
In patients taking amlodipine alone, the following have been reported:
Pri bolnikih, ki so jemali samo amlodipin, so poročali o naslednjih neželenih učinkih:
In patients taking AZILECT and/or other medications used to treat Parkinson’s disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed.
Pri bolnikih, ki jemljejo zdravilo AZILECT in/ali druga zdravila, ki se uporabljajo za zdravljenje Parkinsonove bolezni, so opazili vedenja, kot so kompulzije, obsesivne misli, odvisnost od iger na srečo, prekomerno zapravljanje denarja, impulzivno vedenje in nenormalna povečana spolna sla ali obsedenost s pretiranim predajanjem mislim ali občutkom v povezavi s spolnostjo.
In patients taking AZILECT and/or other medications used to treat Parkinson’s disease, the following have been observed:
Pri bolnikih, ki jemljejo zdravilo AZILECT in/ali druga zdravila, ki se uporabljajo za zdravljenje Parkinsonove bolezni, so opazili:
In patients taking hydrochlorothiazide alone the following additional side effects have been reported:
Pri bolnikih, ki so jemali samo hidroklorotiazid, so poročali še o naslednjih neželenih učinkih:
In patients taking Ilaris the pain was reduced from 74 to 25 units, whereas in patients taking the comparator the pain was reduced from 74 to 35 units.
Pri bolnikih, ki so jemali zdravilo Ilaris se je bolečina znižala s 74 enot na 25, pri tistih, ki so jemali primerjalno zdravilo, pa s 74 na 35 enot.
In patients taking Izba, the average eye pressure (measured at 8 am in the morning) was 19.4, 19.3 and 19.2 mmHg following 2 weeks, 6 weeks and 3 months of treatment, respectively, which matched the pressure seen at similar time points in patients taking Travatan (19.5, 19.3 and 19.3 mmHg).
Pri bolnikih, ki so prejemali zdravilo Izba, je bil povprečen tlak v očesu (merjen ob 8.00 uri zjutraj)
In patients taking Lyxumia in combination with a sulphonylurea and metformin, symptomatic hypoglycaemia occurred in 22.0% of lixisenatide treated patients and in 18.4% of placebo treated patients during the entire treatment period (3.6% absolute difference).
Pri bolnikih, ki so zdravilo uporabljali v kombinaciji s sulfonilsečnino Pri bolnikih, ki so zdravilo uporabljali v kombinaciji s sulfonilsečnino in metforminom, se je simptomatska hipoglikemija med celotnim obdobjem zdravljenja pojavila pri 22,0 % prejemnikov liksenatida in pri 18,4 % prejemnikov placeba (absolutna razlika 3,6 %).
In patients taking moderate CYP3A inhibitors, tolvaptan doses have to be reduced as follows:
Pri bolnikih, ki jemljejo zmerne zaviralce CYP3A, je treba odmerke tolvaptana zmanjšati kot sledi:
In patients taking opioids with constipation, who have tried at least one laxative and had incomplete relief of constipation, Moventig has been shown in clinical trials to increase the number of bowel movements and improve symptoms of constipation caused by opioids.
Klinična preskušanja so pokazala, da zdravilo Moventig poveča število iztrebljanj in izboljša simptome zaprtosti, ki jih povzročajo opioidi, pri bolnikih, ki jemljejo opioide, so zaprti ter so poskusili vsaj eno odvajalo, pa z njim niso dosegli popolnega olajšanja zaprtosti.
In patients taking placebo, the total size of the kidneys increased by 18.8% whereas in those taking Jinarc the increase was 9.6%.
Pri bolnikih, ki so jemali placebo, se je skupna velikost ledvic povečala za 18,8 %, pri bolnikih, ki so jemali zdravilo Jinarc, pa za 9,6 %.
In patients taking Plenadren the cortisol levels achieved were considered to be satisfactory for patients with adrenal insufficiency.
Pri bolnikih, ki so jemali zdravilo Plenadren, je bila dosežena zadostna raven kortizola za bolnike z adrenalno insuficienco.
In patients taking PREZISTA and raltegravir (for HIV infection), rashes (generally mild or moderate) may occur more frequently than in patients taking either medicine separately.
Pri bolnikih, ki jemljejo zdravilo PREZISTA skupaj z raltegravirjem (pri okužbi s HIV), se izpuščaji lahko pojavijo pogosteje (večinoma blagi do zmerni), kot pri bolnikih, ki teh dveh zdravil ne jemljejo skupaj.
In patients taking rasagiline and/or other medications used to treat Parkinson’s disease, the following have been observed:
Pri bolnikih, ki jemljejo razagilin in/ali druga zdravila, ki se uporabljajo za zdravljenje Parkinsonove bolezni, so opazili:
In patients taking Rasagiline Mylan and/or other medications used to treat Parkinson’s disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed.
Pri bolnikih, ki jemljejo zdravilo Razagilin Mylan in/ali druga zdravila, ki se uporabljajo za zdravljenje Parkinsonove bolezni, so opazili vedenja, kot so kompulzije, obsesivne misli, odvisnost od iger na srečo, prekomerno zapravljanje denarja, impulzivno vedenje in nenormalna povečana spolna sla ali obsedenost s pretiranim predajanjem mislim ali občutkom v povezavi s spolnostjo.
In patients taking Rasagiline ratiopharm and/or other medications used to treat Parkinson’s disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed.
Pri bolnikih, ki jemljejo zdravilo Razagilin ratiopharm in/ali druga zdravila, ki se uporabljajo za zdravljenje Parkinsonove bolezni, so opazili vedenja, kot so kompulzije, obsesivne misli, odvisnost od iger na srečo, prekomerno zapravljanje denarja, impulzivno vedenje in nenormalna povečana spolna sla ali obsedenost s pretiranim predajanjem mislim ali občutkom v povezavi s spolnostjo.
In patients taking Rasagiline ratiopharm and/or other medications used to treat Parkinson’s disease, the following have been observed:
Pri bolnikih, ki jemljejo zdravilo Razagilin ratiopharm in/ali druga zdravila, ki se uporabljajo za zdravljenje Parkinsonove bolezni, so opazili:
In patients taking some of the components of Stribild, certain rare but serious side effects have been seen including lactic acidosis (excess lactic acid in the blood) and severe kidney problems.
Pri bolnikih, ki so prejemali nekatere od sestavin zdravila Stribild, so poročali o redkih, vendar resnih neželenih učinkih, vključno z laktacidozo (preveliko količino mlečne kisline v krvi) in resnimi težavami z ledvicami.
In patients taking strong CYP3A inhibitors (see section 4.5), tolvaptan doses have to be reduced as follows:
Za bolnike, ki jemljejo močne zaviralce CYP3A (glejte poglavje 4.5), je treba odmerke tolvaptana zmanjšati kot sledi:
In patients that discontinued therapy at 24 weeks, according to protocol, the relapse rate was 11/15.
Pri bolnikih, ki so zdravljenje prekinili v 24. tednu, v skladu s protokolom, je bila stopnja relapsa 11/15.
In patients that had moderate or severe elevation in one or more liver function tests at baseline, ticagrelor plasma concentrations were on average similar or slightly higher as compared to those without baseline elevations.
Bolniki z zmernim ali hudim izhodiščnim zvišanjem enega ali več jetrnih funkcijskih testov so imeli koncentracijo ticagrelorja v plazmi v povprečju podobno ali rahlo višjo kot tisti brez izhodiščnih zvišanj.
In patients that suffer from severe long term pain, there is a higher likelihood of suicide and attempted suicide than in the general population.
Pri bolnikih z močno kronično bolečino sta samomor in poskus samomora pogostejša kot v splošni populaciji.
In patients treated for DVT and PE with 150 mg dabigatran etexilate twice daily, the dabigatran geometric mean trough concentration, measured within 10−16 hours after dose, at the end of the dosing interval (i.e.
Pri bolnikih, ki so se zdravili zaradi GVT in PE s 150 mg dabigatran eteksilata dvakrat na dan, je geometrična sredina koncentracije pred naslednjim odmerkom, izmerjena v 10 do 16 urah po odmerku, ob koncu odmernega intervala (tj.
In patients treated for hematological malignancies, B cell recovery began within 6 months of treatment and generally returned to normal levels within 12 months after completion of therapy, although in some patients this may take longer (up to a median recovery time of 23 months post-induction therapy).
Pri bolnikih, ki so se zdravili zaradi hematoloških malignih bolezni, so se celice B začele obnavljati v 6 mesecih zdravljenja, njihovo število pa se je v splošnem vrnilo v normalno stanje v 12 mesecih po končanem zdravljenju, pri nekaterih bolnikih pa je lahko trajalo dlje (mediani čas okrevanja je bil do 23 mesecev po indukcijskem zdravljenju).
In patients treated for malignant melanoma, liver function and white blood cell (WBC) count and differential must be monitored weekly during the induction phase of therapy and monthly during the maintenance phase of therapy.
Pri bolnikih, ki se zdravijo zaradi malignega melanoma, morate spremljati delovanje jeter in število levkocitov ter diferencialno krvno sliko, in sicer enkrat na teden v uvajalni fazi zdravljenja, med vzdrževalno fazo zdravljenja pa enkrat na mesec.
In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of CIAMBRA is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Pri bolnikih, pri katerih zdravimo nedrobnocelični pljučni karcinom po predhodni kemoterapiji, je priporočeni odmerek zdravila CIAMBRA 500 mg/m2 TP, dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega ciklusa.
In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed Fresenius Kabi is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Pri bolnikih, pri katerih zdravimo nedrobnocelični pljučni rak po predhodni kemoterapiji, je priporočeni odmerek zdravila Pemetreksed Fresenius Kabi 500 mg/m2 BSA, dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega cikla.
In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed Hospira is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Pri bolnikih, pri katerih zdravimo nedrobnocelični pljučni karcinom po predhodni kemoterapiji, je priporočeni odmerek zdravila Pemetreksed Hospira 500 mg/m2 TP, dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega ciklusa.
In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed Lilly is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Pri bolnikih, pri katerih zdravimo nedrobnocelični pljučni karcinom po predhodni kemoterapiji, je priporočeni odmerek zdravila Pemetreksed Lilly 500 mg/m2 TP, dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega ciklusa.
In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed medac is 500 mg/m² BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Pri bolnikih, pri katerih zdravimo nedrobnocelični pljučni karcinom po predhodni kemoterapiji, je priporočeni odmerek zdravila Pemetreksed medac 500 mg/m² TP, dan kot intravenska infuzija v 10 minutah prvi dan vsakega 21-dnevnega ciklusa.
In patients treated for prevention of atherothrombotic events after an acute coronary syndrome (ACS), bleeding of any type or severity was reported with an event rate of 22 per 100 patient years.
Pri bolnikih, zdravljenih za preprečevanje aterotrombotičnih dogodkov po akutnem koronarnem sindromu (AKS), so poročali o krvavitvah vseh vrst in resnosti s pogostnostjo 22 na 100 bolnikov-let.
In patients treated for prevention of cardiovascular death and myocardial infarction after an acute coronary syndrome (ACS), bleeding of any type or severity was reported with an event rate of 22 per 100 patient years.
Pri bolnikih, zdravljenih za preprečevanje kardiovaskularne smrti in miokardnega infarkta po akutnem koronarnem sindromu (AKS), so poročali o krvavitvah vseh vrst in resnosti s pogostnostjo 22 na
In patients treated for prevention of cardiovascular death and myocardial infarction after an acute coronary syndrome (ACS), bleeding of any type or severity was reported with an event rate of 22 per 100 patient years.
Pri bolnikih, zdravljenih za preprečevanje kardiovaskularne smrti in miokardnega infarkta po akutnem koronarnem sindromu (AKS), so poročali o krvavitvah vseh vrst in resnosti s pogostnostjo 22 na 100 bolnikov-let.
In patients treated for prevention of stroke and systemic embolism, bleeding of any type or severity was reported with an event rate of 28 per 100 patient years, and anaemia with an event rate of 2.5 per 100 patient years.
Pri bolnikih, ki so zdravilo Xarelto prejemali za preprečevanje možganske kapi in sistemske embolije, so se krvavitve vseh vrst in resnosti pojavile s pogostnostjo 28 na 100 bolnikov-let, anemija pa 2,5 na 100 bolnikov-let.
In patients treated with 6 consecutive monthly injections of Eylea 2mg, there was a consistent, rapid and robust morphologic response (as measured by improvements in mean CRT) observed.
Pri bolnikih, zdravljenih s 6 zaporednimi mesečnimi injekcijami zdravila Eylea 2 mg je bil opažen dosleden, hiter in robusten morfološki odgovor (na podlagi meritev izboljšanj povprečne OCT).
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than
Glede na farmakokinetične podatke o monoterapiji z docetakselom v odmerku 100 mg/m2 je priporočljivi odmerek docetaksela za bolnike, ki imajo transaminazi (ALT, AST ali obe) zvišani nad 1,5-kratno zgornjo mejo normalnega območja (ULN) in alkalno fosfatazo nad 2,5-kratno ULN,
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
Pri bolnikih, ki se zdravijo s 100 mg docetaksela/m2 v monoterapiji, ki imajo serumski transaminazi (ALT, AST ali obe) zvišani nad 1,5-kratno ZMRO in hkrati zvišano serumsko alkalno fosfatazo nad 2,5-kratno ZMRO, obstaja večja nevarnost hudih neţelenih učinkov, kot so smrt zaradi zastrupitve, vključno s sepso in gastrointestinalno krvavitvijo, ki sta lahko usodni, febrilna nevtropenija, okuţbe, trombocitopenija, stomatitis in astenija.
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
Pri bolnikih, ki se zdravijo s 100 mg docetaksela/m2 v monoterapiji, ki imajo serumski transaminazi (ALT, AST ali obe) zvišani nad 1,5-kratno ZMRO in hkrati zvišano serumsko alkalno fosfatazo nad 2,5-kratno ZMRO, obstaja večja nevarnost hudih neželenih učinkov, kot so smrt zaradi zastrupitve, vključno s sepso in gastrointestinalno krvavitvijo, ki sta lahko usodni, febrilna nevtropenija, okužbe, trombocitopenija, stomatitis in astenija.
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
Pri bolnikih, ki se zdravijo s 100 mg docetaksela/m2 v monoterapiji, ki imajo serumski transaminazi (ALT, AST ali obe) zvišano nad 1,5-kratno ZMRO in hkrati zvišano serumsko alkalno fosfatazo nad 2,5-kratno ZMRO, obstaja večja nevarnost hudih neţelenih učinkov, kot so smrt zaradi zastrupitve, vključno s sepso in gastrointestinalno krvavitvijo, ki sta lahko usodni, febrilna nevtropenija, okuţbe, trombocitopenija, stomatitis in astenija.
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
Pri bolnikih, ki se zdravijo s 100 mg docetaksela/m2 v monoterapiji, ki imajo serumski transaminazi (ALT, AST ali obe) zvišano nad 1,5-kratno ZMRO in hkrati zvišano serumsko alkalno fosfatazo nad 2,5-kratno ZMRO, obstaja večja nevarnost hudih neželenih učinkov, kot so smrt zaradi zastrupitve, vključno s sepso in gastrointestinalno krvavitvijo, ki sta lahko usodni, febrilna nevtropenija, okužbe, trombocitopenija, stomatitis in astenija.
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
Pri bolnikih, zdravljenih s 100 mg docetaksela/m2 v monoterapiji, ki imajo serumski transaminazi (ALT, AST ali obe) zvišani nad 1,5-kratno ULN in hkrati zvišano serumsko alkalno fosfatazo nad 2,5- kratno ULN, obstaja večja nevarnost hudih neželenih učinkov, kot so smrti zaradi zastrupitve, vključno s sepso in gastrointestinalno krvavitvijo, ki sta lahko usodni, febrilne nevtropenije, okužb, trombocitopenije, stomatitisa in astenije.
In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate ≥ 10% higher in patients who were 65 years of age or greater compared to younger patients.
Pri bolnikih zdravljenih z docetakselom vsake tri tedne, ki so bili starejši od 65 let, je bila incidenca pojavljanja z zdravljenjem povezanih sprememb na nohtih  10 % večja v primerjavi z mlajšimi bolniki.
In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate  10% higher in patients who were 65 years of age or greater compared to younger patients.
Pri bolnikih zdravljenih z docetaksel vsake tri tedne, ki so bili starejši od 65 let, je bila incidenca pojavljanja z zdravljenjem povezanih sprememb na nohtih  10 % večja v primerjavi z mlajšimi bolniki.
In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate  10% higher in patients who were 65 years of age or greater compared to younger patients.
Pri bolnikih zdravljenih z docetakselom vsake tri tedne, ki so bili starejši od 65 let, je bila incidenca pojavljanja z zdravljenjem povezanih sprememb na nohtih  10 % večja v primerjavi z mlajšimi bolniki.